Akers Biosciences Completes Clinical Trial for Rapid Chlamydia Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Akers Biosciences (AKER) Shares Pop Higher Upon Completion of PIFA/Chlamydia Rapid Assay Clinical Trial
June 30, 2016 9:00 AM EDTAkers Biosciences (Nasdaq: AKER) shares are popping higher in early trading after the company announced that it completed a clinical trial of its PIFA/Chlamydia Rapid Assay, the first rapid test for Chlamydia diagnosis using a finger stick blood sample.
Akers is up over 17 percent ahead of the opening bell.
... More